Plasmodium falciparum Antigenic Species

Plasmodium falciparum (P. falciparum) infection is life-threatening. Several antigens play important roles during infection.

• Erythrocyte surface antigens: P. falciparum interacts with red blood cells by surface antigens (MSP1, MSP2 and MSP3), and then invades red blood cells.
• Circumsporozoite protein: It is one of the major antigens on the surface of P. falciparum trophozoites and sporozoites, which plays a key role in allowing parasites to invade human cells.
• Plasmodium lysine-rich protein (PfEMP1): PfEMP1 is the major antigen expressed by the parasite in red blood cells, which enables the parasite to evade attack by the host's immune system.
• Red blood cell invasion proteins: They are involved in the invasion of red blood cells by P. falciparum, containing RH, EBA and AMA families.

Studying the properties and functions of these antigens helps provide the basis for malaria prevention, diagnosis, and treatment.

P. falciparum Antigen Production Services at CD BioGlyco

The production of P. falciparum antigens generally involves the following steps.

• Gene cloning and expression construction

CD BioGlyco clones the coding sequence of the target antigen from the genome of P. falciparum and inserts it into an appropriate expression vector.

• Expression system selection

CD BioGlyco selects an appropriate expression system, such as E. coli, mammalian cells, or eukaryotic expression systems, to achieve efficient antigen expression.

• Cell culture and expression optimization

CD BioGlyco introduces the expression vector into appropriate host cells and performs cell culture and expression optimization under appropriate conditions to obtain high-yield antigens.

• Antigen purification

CD BioGlyco uses various purification technologies such as affinity chromatography, ion exchange chromatography, and gel filtration chromatography to purify the expressed antigen to obtain high-purity antigen samples.

• Antigen immunogenicity assessment

CD BioGlyco performs immunogenicity assessment of produced antigens, including in vitro and in vivo experiments, to determine the potency and suitability of the antigen in inducing an immune response. In addition, we have established a reliable Glyco™ Vaccine Development Platform, which provides high-quality vaccine development services based on P. falciparum antigens, such as vaccine formula optimization, expression system selection, immune effect evaluation, etc.

Fig.1 P. falciparumantigen production services. (CD BioGlyco)

Applications

• To produce and purify specific P. falciparum antigens, researchers evaluate their immunogenicity, protective efficacy, and safety to further develop effective vaccines against P. falciparum.
• Preparing high-purity P. falciparum antigen samples is applied to the development of diagnostic reagents to help determine whether infected individuals carry P. falciparum parasites.
• P. falciparum antigens produced are used to conduct in vitro or in vivo drug screening experiments to evaluate the ability of candidate compounds to inhibit parasites and provide support for malaria treatment research.

Advantages

• Our scientists are familiar with the biological characteristics of P. falciparum and the production process of related antigens, we provide high-quality antigen products and vaccine development.
• CD BioGlyco adopts strict quality control standards to ensure that the antigen products produced have high purity, stability, and activity.
• CD BioGlyco produces the required antigens in a short period and delivers them to clients on time.

CD BioGlyco has many years of experience in antigen production and provides a convenient and reliable P. falciparum antigen supply. If you need efficient and high-quality antigens, we are your first choice, please feel free to contact us in time for details.

References

1. Naik, R.S.; et al. Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. The Journal of Experimental Medicine. 2000, 192(11): 1563-1576.
2. Julien, J.; Wardemann, H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nature Reviews Immunology. 2019, 19(12): 761-775.